FDA 483 - Hisun Pharmaceutical (Nantong) Co., Ltd. - July 12, 2024
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Hisun Pharmaceutical (Nantong) Co., Ltd., an API manufacturer in Nantong City, China, received a Form 483 for significant deficiencies observed during an FDA inspection. The firm was cited for inadequate change control for new sampling devices, insufficient deviation investigations leading to repeat sampling errors, and poor equipment cleaning and maintenance practices. Additionally, the inspection revealed a lack of adequate written procedures for equipment cleaning and release.
ID · 562ab22b-99f9-4a2d-a4f2-ac08d4050811